


CLAIM AMENDMENTS

1 - 5. (canceled)

1 6. (New) A pharmaceutical composition for the treatment
2 of pain which consists essentially of:

3 (a) 70 to 95% w/w compound of formula I



I

5 wherein R is a methyl or ethyl group, as active ingredient and

6 (b) 5 to 30 % w/w of dextromethorphan, as a potentiator
7 of the compound of the Formula (I), together with a
8 pharmaceutically acceptable inert carrier.

1 7. (New) The pharmaceutical composition according to
2 claim 6, wherein the compound of formula I, wherein R is a methyl
3 group is present in an amount of 80 to 90% w/w and dextromethorphan
4 is present in an amount of 10 to 20% w/w.

1 8. (New) The pharmaceutical composition according to
2 claim 6 wherein a unit of the composition contains 150 mg
3 tolperisone and 30 mg dextromethorphan in admixture with a
4 pharmaceutically acceptable inert carrier.

1 9. (New) The pharmaceutical composition according to
2 claim 8 wherein the unit of the composition includes a
3 pharmaceutically acceptable inert carrier suitable for oral
4 administration.

1 10. (New) A method of treating and/or inhibiting pain
2 which comprises the step of administering to a patient in need of
3 said treatment, an analgesically effective amount of the
4 pharmaceutical composition defined in claim 6.

1 11. (New) The method of treating and/or inhibiting pain
2 defined in claim 10 wherein the pharmaceutical composition is
3 orally administered to the patient in need of said treatment.

1 12. (New) A synergistic pharmaceutical composition for
2 treating spasticity which consists essentially of as active
3 ingredients:

4 (a) 40 to 60 parts by weight of tolperisone or eperisone;
5 and

6 (b) 10 parts by weight of dextromethorphan, together with
7 a pharmaceutically acceptable inert carrier.

1 13. (New) The pharmaceutical composition according to
2 claim 12 wherein the active ingredients are 40 to 60 parts by
3 weight of tolperisone and 10 parts by weight of dextromethorphan.

1 14. (New) The pharmaceutical composition according to
2 claim 13 wherein a unit of the composition contains 150 mg
3 tolperisone and 30 mg dextromethorphan in admixture with a
4 pharmaceutically acceptable inert carrier.

1 15. (New) The pharmaceutical composition according to
2 claim 12 wherein the unit of the composition includes a
3 pharmaceutically acceptable inert carrier suitable for oral
4 administration.

1 16. (New) A method of treating and/or inhibiting
2 spasticity which comprises the step of administering to a patient
3 in need of said treatment, an anti-spasmodically effective amount
4 of the synergistic pharmaceutical composition defined in claim 12.

1 17. (New) The method of treating and/or inhibiting
2 spasticity defined in claim 16 wherein the pharmaceutical
3 composition is orally administered to the patient in need of said
4 treatment.